Previous

Infensa CSO and co-founder Professor Glenn King elected a Fellow of the Australian Academy of Science
Next

Infensa scientists publish in European Heart Journal showing efficacy of lead drug candidate when administered at relevant timepoints in preclinical models of moderate and severe myocardial infarction